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Abstract
Purpose The problem of drug sensitivity and predicting the
outcome of chemotherapy seems to be of great importance in
hemato-oncological disorders. There are some factors that can
help to predict effects of chemotherapy in chronic lymphocyt-
ic leukemia (CLL), such as presence of del17p, del11q, or
TP53 gene mutations, which result in resistance to purine
analogues and alkylating drugs. Despite the new therapeutic
options introduced recently, purine analogues in combination
with cyclophosphamide and the monoclonal antibody rituxi-
mab is still the gold standard for the first-line treatment of fit
patients with CLL. The aim of this study was to assess wheth-
er the rate of apoptosis caused by one of purine analogues—
fludarabine in cell cultures differs between patients who clin-
ically respond to fludarabine-based chemotherapy and those
who do not respond.
Methods CLL leukemic cells, obtained from peripheral blood
and bone marrow of 23 patients, were cultured in the presence
of fludarabine. After 24 h of incubation, the rate of apoptosis,
indicated by the expression of active caspase-3, was assessed
with flow cytometry and then analyzed regarding clinical re-
sponse to fludarabine-based regimens.
Results The percentage of apoptotic cells induced by
fludarabine was significantly higher in the group of patients
who achieved remission in comparison to the group with no
response to purine analogues therapy. Interestingly, we ob-
served that among the patients who did not respond to chemo-
therapy, the presence of del17p and del11q was detected only
once. Other non-responders had no detectable genetic
abnormalities.
Conclusions Based on these results, it can be presumed that
in vitro drug sensitivity test, which is easy to perform, may
predict the outcome of fludarabine-based chemotherapy in
CLL patients.
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Introduction
Chronic lymphocytic leukemia (CLL) is characterized by the
accumulation of malignant CD19+/CD5+ B cells in blood,
bone marrow, and lymphoid organs [1–3]. The leukemic
transformation is initiated by genomic alterations causing the
deletion of specific micro-RNA genes and increasing the re-
sistance of B cells towards apoptosis [1, 4]. The biology of
CLL is also directly entwined with its microenvironment, in
which accessory cells can promote leukemia cell growth and
survival. Recently, much attention has been focused on the B
cell receptor (BCR) and on chemokine receptors that enable
CLL cells to home to lymphoid tissues and to establish the
leukemia microenvironment [5]. BCR signaling plays an im-
portant pathogenic role, based on structural restrictions of the
BCR, and BCR-dependent survival and growth of the malig-
nant B cells. In CLL, ligand-independent and ligand-
dependent BCR signaling has been characterized. They can
involve mutations of BCR pathway components or be trig-
gered by antigens present in the tissue microenvironment [6].
CLL typically occurs in elderly patients and has a highly
variable clinical course [7]. Some patients have indolent
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disease and never need treatment, but in others, the clinical
course is aggressive and soon after diagnosis requires inten-
sive treatment [8, 9]. This variable clinical course of CLL
makes the role of prognostic factors very important, especially
for distinguishing the group of patients who require intensive
treatment from those who will benefit from milder forms of
therapy. A number of markers of prognostic relevance have
been identified for CLL. Among these markers, biological risk
factors such as the VHmutation status or its surrogate markers
as well as genomic aberrations may have the power to identify
the subgroup of patients with poor prognosis from early stage
patients [9, 10]. Among them deletions of the short arm of
chromosome 17 (del(17p)) or TP53 gene mutation predict
resistance to most available therapies [7].
Recently, substantial strides have been made in the treat-
ment of CLL. The novel class of targeted therapies, such as
two oral tyrosine kinase inhibitors, ibrutinib (Bruton’s kinase
inhibitor) and idelalisib (phosphatidylinositol 3-kinase delta
inhibitor), have received approval for the treatment of CLL
patients. Another promising drugs are BCL-2 protein antago-
nists that induce apoptosis in leukemic cells. The new mono-
clonal antibody—obinutuzumab, has also been recently intro-
duced to the therapy of older patients in combination with
chlorambucil. Despite the new therapeutic options, purine an-
alogues in combination with cyclophosphamide and the
monoclonal antibody rituximab is still the gold standard for
the first-line treatment of fit patients with CLL [11]. Some
patients, however, are refractory to purine analogues, especial-
ly those with del17p or del11q. The presence of other, not
explored yet, factors may be responsible for therapy resistance
as well. Thus, exploring the process of drug-induced apoptosis
in vitro may be of great importance for predicting the suscep-
tibility of leukemic cells to the drug, especially if it would
reflect this susceptibility in vivo.
In this study, we attempted to assess the rate of CLL cell
apoptosis caused by one of purine analogues—fludarabine.
The experiments were performed in short-term cell cultures
of peripheral blood and bone marrow supplemented with this
drug. We analyzed the percentage of cells with active caspase-
3 expression. Then, the apoptosis rate was assessed as a mark-
er predicting the outcome of chemotherapy.
Materials and methods
Patients
The study was approved by the local ethical committee. Pe-
ripheral blood and bone marrow samples were obtained from
23 patients after informed consent. Diagnosis of CLL was
based on a clinical examination and morphological and im-
munological criteria. The patients were enrolled to the study
prior to the onset of therapy with fludarabine-based regimens
and were not treated previously with any chemotherapeutic
agents.
Cell culture
Mononuclear cells were isolated by density gradient centrifu-
gation using Lymphoprep (Nycomed, Norway). Then, the
cells were cultured in medium consisting of RPMI 1640 with
2 mM L-glutamine, 100 units/ml penicillin, 100 μg/ml strep-
tomycin, and 10 % fetal calf serum (FCS) at a final concen-
tration of 2×106 cells/ml. This culture medium was supple-
mented with fludarabine (Schering AG, Germany) at a con-
centration of 1 μg/ml. We selected such a concentration of
fludarabine on the basis of our preliminary experiments in
CLL cultures, in which this concentration induced significant
number of apoptosis with spontaneous apoptosis that did not
exceed 50 % of the total cell culture [12]. The cells were
cultured at 37 °C in a 5 % CO2 atmosphere, and they were
exposed to the drugs for 24 h. Respective cell samples incu-
bated in the absence of any drug for periods of time equivalent
to the drug-treated cells were used as a negative control.
Immunocytochemical detection of active caspase-3
as a marker of apoptosis
The blood and bone marrow samples that had been treated in
culture with fludarabine (∼105 cells) were initially incubated
for 15 min with anti-CD19 PerCP and anti-CD5 APC-conju-
gated monoclonal antibody (MoAb) (DAKO, Denmark) at
room temperature. After fixation and permeabilization proce-
dures (IntraPrep kit, Immunotech, France), the cells were in-
cubated with anti-active caspase-3 MoAb, PE conjugated
(Pharmingen, USA), or an isotype-matched negative control
(Dako, Denmark) in darkness at room temperature for 15 min.
After washing, the labelled cells were analyzed by multi-
parameter flow cytometry.
Fluorescence measurement
The samples were measured with a FACSCalibur (Becton
Dickinson) using standard emission filters for green and red
fluorescence and CellQuest software. The CD5+/CD19+ pop-
ulation was initially gated and further analysis was carried out
for this population. Ten thousand cells were measured per
sample. To determine the frequency of apoptosis, the percent-
age of active caspase-3 cells, corresponding to that in the
control cells, was calculated. Intra-assay variation of the flow
cytometry test was assessed using two acquisitions per assay,
while inter-assay variation was assessed by performing in the
chosen cases two cell cultures of the same patient on different
days. Both intra- and inter-assay variation were lower than
10 %. Representative dot plots illustrating the expression of
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caspase-3 by CD19+/CD5+ CLL cells in cultures with
fludarabine are presented in Fig. 1.
Flow cytometric detection of ZAP-70 and CD38
as prognostic factors
A total of 1×106 peripheral blood cells were stained with the
monoclonal antibodies CD19 PE (BD Pharmingen), CD5
CyChrome (Caltag Laboratories, USA), or CD3 PE (BD
Pharmingen). Following membrane staining, the cells were
fixed in 1 % paraformaldehyde solution in PBS for 15 min
at room temperature and permeabilized with 70 % ethanol for
one hour at −20 °C. After washing with PBS, anti-ZAP-70
antibody (Biomol Research Laboratories, USA) labelled by
the ZenonTM Alexa Fluor® 488 Mouse IgG2a Labeling Kit
(Molecular Probes, USA) was added to the sample tubes. The
samples were incubated with the reagent for 30 min at room
temperature, washed once with PBS, and analyzed by flow
cytometry (FACSCalibur, Becton Dickinson).
To assess CD38 expression, peripheral blood mononu-
clear cells were stained with CD38 FITC, CD19 PE, CD5
CyChrome, or IgG1 isotypic control MoAbs. The cells were
incubated for 20 min at room temperature. Finally, the cells
were washed and analyzed by flow cytometry.
Fluorescence in situ hybridization
Fluorescence in situ hybridization (FISH) method was
used for an analysis of chromosome alterations charac-
teristic of CLL that are relevant markers of prognosis.
The locus-specific probes for 11q22.3 (LSI ATM),
17p13.1 (LSI TP53), 13q.14.3 (D13S319), and the chro-
mosome 12 centromere (CEP12) (Abbott Diagnostics)
were used and FISH was performed according to the
manufacturer’s instructions. Probes were denatured at
73 °C for 5 min and then applied to the determined areas
on the slides. Following overnight hybridization at
37 °C, the slides were washed and air-dried in the dark-
ness. Then, the slides were stained with DAPI and stored
at −20 °C in the darkness. The samples were analyzed
using the BX51 fluorescence microscope (OLYMPUS)
and the CytoVision image analyzing system. At least
200 nuclei were analyzed for each probe with the cutoff
value of 20 %.
A
B
Fig. 1 The representative flow
cytometry dot plots showing
expression of caspase-3 by
CD19+/CD5+ cells of peripheral
blood in CLL patients that were
induced to undergo apoptosis by
fludarabine. a Patient of
responder group with response to
fludarabine-based chemiotherapy
in vivo. b Patient of non-
responder group with no response
to fludarabine-based
chemotherapy in vivo
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Clinical response to fludarabine-based treatment
regimens
The assessment of clinical response to chemotherapy with
fludarabine-based regimens was performed in the studied
group of patients. We used the criteria of response to treatment
proposed by WG-IWCLL in 2008 [13] based on WG-NCI
criteria from 1996 [14]. According to these criteria, complete
response requires the absence of symptoms and
organomegaly, normal complete cell counts of peripheral
blood, and less than 30 % of lymphocytes in bone marrow
for at least 2 months. When size of the lymph nodes, spleen
and liver, together with the peripheral blood data, were at least
50% better than pre-treatment values, the partial response was
achieved. Other patients were considered non-responders.
Statistical analysis
The statistical analysis was performed using STATISTICA
10.0 software for Windows. We used Mann-Whitney U test
for two-independent-group analyses. p<0.05 was considered
to be statistically significant.
Results
Active caspase-3 expression by CD19+/CD5+ peripheral
blood and bone marrow cells in cultures with fludarabine
We detected active caspase-3 expression inmalignant CD19+/
CD5+ cells in all cell cultures from both peripheral blood and
bone marrow after 24 h, similarly to our previously published
results [12]. An increase in the percentage of caspase-3-
positive cells was observed after 24 h in control cultures (cells
without drugs) relative to the 0-h baseline control. This phe-
nomenon was caused by spontaneous apoptosis of malignant
cells in in vitro conditions, as it has been reported for CLL
[15]. In cell cultures with fludarabine, the percentage of apo-
ptotic cells after 24 h was obviously higher than at 0 h. It was
also significantly higher than the percentage of apoptotic cells
in control cultures without drugs after 24 h. The results
(presented as the mean±standard deviation) are shown in the
Table 1 attached as a supplementary document.
Assessment of chemotherapy response
The patients enrolled into the study were treated with the
following fludarabine-based regimens:
– FC (fludarabine + cyclophosphamide), 11 persons
– TF (thalidomide + fludarabine), 5 persons
– FCR (fludarabine + cyclophosphamide + rituximab), 6
persons
– FCA (fludarabine + cyclophosphamide + alemtuzumab),
1 person
For all patients, these regimens were first-line treatment.
Thirteen patients achieved complete remission, five partial
remission, while five had no treatment response, what was
an indication to change the treatment.
Comparison of apoptosis rate in in vitro cultures
with response to fludarabine-based chemotherapy
To assess the rate of apoptosis induced by fludarabine in the
group of patients with clinical response to treatment and in the
group of non-responders, we measured the expression of active
caspase-3 in CD19+/CD5+ peripheral blood and bone marrow
samples. Figure 2 illustrates the drug-induced increase in the
frequency of apoptotic cells above the level of spontaneous
apoptosis seen in the untreated 24-h parallel control cultures
in both analyzed groups. The frequency of fludarabine-induced
apoptosis in peripheral blood cultures of responding group was
significantly higher than in non-responding one, and the same
was true when compared with bone marrow cultures. Interest-
ingly, among the patients who did not respond to chemothera-
py, only in one case the presence of del17p and in one case del
11q were detected, while other persons had no genetic abnor-
malities. Similarly, only two persons were ZAP-70 positive and
two were CD38+. The characteristic of non-responding pa-
tients is shown in Table 1.
Discussion
Purine analogues are currently widely used in CLL patients.
Three of them, fludarabine, pentostatin, and cladribine (2-
CdA), were proved to have an effect on leukemic cells. They
demonstrate antitumor activity in some ways such as direct
interference with DNA and RNA synthesis, DNA repair
mechanisms, induction of apoptosis, control of the cell cycle,
and signal transduction pathways [16, 17]. Fludarabine re-
mains the best studied compound of these three in CLL pa-
tients. Purine analogues have been reported to induce higher
remission rates when they are employed as a first-line therapy
compared with other treatment regimens containing alkylating
agents or corticosteroids [18–21]. A major advance in CLL
treatment was achieved by the combined use of different
drugs. Thus, fludarabine-based therapies, in particular, its
combination with other drugs such as cyclophosphamide or
monoclonal antibody rituximab, were investigated in clinical
trials [22, 23]. It has been proved that patients receiving
fludarabine and rituximab had a better progression-free
survival and overall survival than patients receiving
fludarabine alone that represent a significant advance in
CLL therapy [24, 25].
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A number of markers of prognostic relevance have been
identified for CLL patients, such as laboratory parameters
reflecting the tumor burden or disease activity and markers
related to the biology of the leukemia. The latter include ge-
netic markers (like genomic aberrations, gene abnormalities
(p53 and ATM), and the mutation status of the variable
segment of immunoglobulin heavy chain genes (IgVH)) or
surrogate markers for these factors such as ZAP-70 or CD38
[9, 25, 26]. Some of the prognostic factors can be used as
predictors of the outcome of chemotherapy. Deletions of the
short arm of chromosome 17 (del17p) are found in 5–8 % of
chemotherapy-resistant patients. These deletions almost al-
ways include band 17p13, where the prominent tumor sup-
pressor gene TP53 is located. CLL patients carrying a del17p
clone show marked resistance to genotoxic chemotherapies
that cannot be overcome by the addition of anti-CD20 anti-
bodies [7, 27]. Mutations of TP53 are associated with very
poor prognosis and are found in 4–37 % of patients with CLL
[28]. The majority of patients with cytogenetically detected
del17p show mutations in the remaining TP53 allele. In cases
without del17p, TP53 mutations are much rarer, but have a
similarly detrimental effect on chemotherapy response and
overall survival [29]. However, the assessment of TP53 mu-
tation needs complicated and time-consuming methods, not
widely available.
In the presented study, we tried to assess whether the rate of
apoptosis caused by fludarabine in vitro can predict the out-
come of chemotherapy in vivo. The experiments were per-
formed in cultures of blood and bone marrow cells obtained
from CLL patients prior to the onset of fludarabine-based
treatment. The cultures were supplemented with fludarabine,
and the percentage of caspase-3-positive cells after a 24-h
period was determined. The results of the study showed sta-
tistically significant differences in apoptosis rate between the
group of responders and non-responders as far as clinical re-
sponse was concerned. The percentage of apoptotic cells was
higher both in peripheral blood and bone marrow samples in
the group of patients who obtained clinically complete or par-
tial remission in comparison to the group with no response to
fludarabine therapy. Interestingly, we observed that among the
patients who did not respond to chemotherapy only in one
case the presence of del17p and in one case del11q predicting
purine analogues resistance, were detected. Other persons of
this group had no genetic abnormalities. Nevertheless, it is
true that we did not analyze the TP53 mutations in the group
of our patients. Such an analysis is elaborate, time-consuming,
and impossible to perform in many hospitals. On the basis of
our results, it can be concluded that quite easy to perform and
simple assessment of apoptosis in drug-supplemented cultures





Fig. 2 Percentage of caspase-3-positive leukemic CD19+/CD5+ cells in
24-h fludarabine-induced cell cultures in group of patients who clinically
respond to fludarabine-based chemotherapy (n=18) versus group of non-
responders (n=5). Data represent the drug-induced increase in the
percentage of apoptotic cells above the respective values observed
in control cultures of the same cell population. Statistically significant
differences are indicated. a Peripheral blood samples. b Bone marrow
samples
Table 1 Clinical characteristic of
patients who did not respond to
the therapy based on fludarabine
regimens
Patient number Rai stadium ZAP-70 CD38 Cytogenetic characteristic
1 4 − − No changes
2 4 + + No changes
3 2 + + del17p
4 2 − − No changes
5 1 − − del11q
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our study, only two persons of the non-responders group
expressed worse prognostic markers such as ZAP-70 and
CD38, which indicates usefulness of the apoptosis test in
predicting the outcome of therapy even in patients without
expression of worse prognostic markers.
The seminal work in the field of in vitro prediction of
clinical outcome in CLL was reported by Bosanquet et al.
[30–32]. The authors used the differential staining cyto-
toxicity (DiSC) assay, as ex vivo apoptotic drug response
test, to identify the sensitivity or resistance to fludarabine
of lymphocytes from CLL patients. The results were com-
pared with subsequent patient treatment, response, and
survival. Treating fludarabine-test-resistant patients with
fludarabine in vivo resulted in poor response and short
survival compared with fludarabine-test-sensitive patients
[30]. It was shown that fludarabine-test-resistance by
DiSC assay is a powerful independent prognostic factor
for CLL patients, which was in accordance with our re-
sults. The authors concluded that the DiSC assay could be
considered a cost-effective guide to the treatment of
chronic lymphocytic leukemia [31, 32].
Bromidge et al. [33] assessed the in vitro sensitivity of CLL
cells to purine analogues and its correlation with clinical
course in the group of 51 persons. Their results showed that
the rate of apoptosis in cell cultures was comparable between
group of patients who needed treatment and the group with
stable disease. For this reason, such a test cannot be used to
predict the time to start the therapy. Similarly to our study, the
authors showed that sensitivity of leukemic cells to in vitro
induced apoptosis correlated with clinical effects of therapy.
Castejon et al. [34] analyzed fludarabine- and cladribine-
induced apoptosis of CLL cells in vitro in comparison to
in vivo response to chemotherapy with these drugs. The anal-
ysis was performed in the group of 50 CLL patients. Similarly
to our results, in vitro apoptosis was in significant correlation
with clinical response to treatment.
Żołnierczyk et al. [35] analyzed ex vivo sensitivity of leu-
kemic cells obtained from CLL patients to conventional pu-
rine analogues and the selective CDK inhibitor R-roscovitine
with and without the addition of an alkylating agent, prior to
the onset of in vivo therapy. The kinetics and rate of sponta-
neous and drug-induced apoptosis of CLL cells under ex vivo
conditions differed significantly between patients, reflecting
the variability observed during in vivo treatment. Similarly to
our results, the authors concluded that ex vivo testing might be
useful for identifying the most potent first-line therapeutic
regimen for specific CLL patients and possibly for the design
of therapies tailored for individual CLL patients [35]. We
showed additionally that sensitivity of leukemic cells to purine
analogues in vitro seemed to be independent of cytogenetic
changes detected in cells.
Recently, it has been reported that not only drug-induced
apoptosis but also spontaneous programmed death may be a
simple prognostic test which can predict the course of the
disease and response to treatment. Witkowska et al. [36] com-
pared the level of spontaneous apoptosis with prognostic fac-
tors and clinical course of the disease in 135 treatment naive
patients with CLL. Rate of apoptosis in patients with stable
disease was found to be significantly higher than in the group
with progressive course of the disease. Furthermore, the level of
apoptosis correlated inversely with the progression-free survival.
In conclusion, the obtained results indicate that the sensi-
tivity of CLL cells to fludarabine induced apoptosis in in vitro
conditions may reflect the effects of these drugs in vivo. As-
sessment of drug-induced apoptosis in cell cultures seems to
be an easy to perform and simple test predicting the outcome
of chemotherapy with fludarabine CLL patients.
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